600529.SH
山东药玻
SSE · Consumer Cyclical · Packaging & Containers · CN
CNY 18.72
−0.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.5B | 4.5B | 4.9B | 4.8B | 4.2B |
| Cost of Revenue | 3.0B | 3.0B | 3.3B | 3.4B | 3.1B |
| Gross Profit | 1.5B | 1.5B | 1.6B | 1.4B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 161.8M | 174.8M | 151.8M | 137.9M | 138.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 242.6M | 232.4M | 215.8M | 188.0M | 144.1M |
| Selling & Marketing Expense | 116.1M | 107.7M | 129.7M | 147.5M | 110.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 572.9M | 550.0M | 513.7M | 484.7M | 385.1M |
| Cost and Expenses | 3.6B | 3.5B | 3.8B | 3.9B | 3.4B |
| Operating Income (EBIT) | 812.9M | 838.0M | 1.1B | 916.4M | 711.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 803.1M | 830.8M | 1.1B | 910.8M | 708.1M |
| Income Tax Expense | 135.9M | 141.2M | 167.8M | 135.0M | 89.8M |
| Bottom Line | |||||
| Net Income | 667.2M | 689.6M | 943.0M | 775.8M | 618.3M |
| Earnings from Cont. Ops | 667.2M | 689.6M | 943.0M | 775.8M | 618.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 667.2M | 689.6M | 943.0M | 775.8M | 618.3M |
| Per Share | |||||
| Basic EPS | CN¥1.00 | CN¥1.04 | CN¥1.42 | CN¥1.17 | CN¥1.03 |
| Diluted EPS | CN¥1.00 | CN¥1.04 | CN¥1.42 | CN¥1.17 | CN¥1.03 |
| Revenue Per Share | CN¥6.74 | CN¥6.75 | CN¥7.39 | CN¥7.19 | CN¥6.98 |
| Shares | |||||
| Basic Shares Outstanding | 670.7M | 663.1M | 664.1M | 663.1M | 600.3M |
| Diluted Shares Outstanding | 670.7M | 663.1M | 664.1M | 663.1M | 600.3M |
| Profitability Metrics | |||||
| EBITDA | — | 1.2B | 1.5B | 1.2B | 1.0B |
| D&A | — | 389.7M | 385.2M | 325.1M | 295.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026